Journal: International Journal of Molecular Sciences

Article Title: Coriloxin Exerts Antitumor Effects in Human Lung Adenocarcinoma Cells

doi: 10.3390/ijms23073991

Figure Lengend Snippet: Influence of coriloxin on BEAS2B, A549, and CL1-5 cell viability. ( A ) Chemical composition of the isolated coriloxin. Following treatment with various concentrations of coriloxin, ( B ) BEAS2B, ( C ) A549, and ( D ) CL1-5 cells were subjected to the MTT assay. Results shown are percentages of the solvent control group (0.01% DMSO). These results are representative of two independent experiments performed, at least, in triplicate. Data are expressed as mean ±SD.

Article Snippet: Our findings suggest that coriloxin can be used as a multitarget anticancer agent.

Techniques: Isolation, MTT Assay, Solvent, Control

Journal: International Journal of Molecular Sciences

Article Title: Coriloxin Exerts Antitumor Effects in Human Lung Adenocarcinoma Cells

doi: 10.3390/ijms23073991

Figure Lengend Snippet: Antiproliferative effects of coriloxin on lung cancer cells. The proliferation activity of ( A ) A549 and ( B ) CL1-5 cells ( n = 6 per group) treated with coriloxin for 24, 48, or 72 h was examined. Each experiment was performed, at least, in triplicate, and the values were reported as mean ± SD. * p < 0.05 indicates a significant difference from the solvent control group (0.01% DMSO).

Article Snippet: Our findings suggest that coriloxin can be used as a multitarget anticancer agent.

Techniques: Activity Assay, Solvent, Control

Journal: International Journal of Molecular Sciences

Article Title: Coriloxin Exerts Antitumor Effects in Human Lung Adenocarcinoma Cells

doi: 10.3390/ijms23073991

Figure Lengend Snippet: Anticlonogenic effects of coriloxin on CL1-5 cells. Representative images and integrated results of cells ( n = 4 per group) under the ( A ) anchorage-dependent and ( B ) anchorage-independent clonogenic assays are presented. The graphs summarize the analytical results. Values are reported as means ±SD ( n ≥ 3). * p < 0.05 indicates a significant difference from the solvent control group (0.01% DMSO). Scale bars, 1 cm.

Article Snippet: Our findings suggest that coriloxin can be used as a multitarget anticancer agent.

Techniques: Solvent, Control

Journal: International Journal of Molecular Sciences

Article Title: Coriloxin Exerts Antitumor Effects in Human Lung Adenocarcinoma Cells

doi: 10.3390/ijms23073991

Figure Lengend Snippet: Antimigratory and anti-invasive effects of coriloxin on CL1-5 cells. ( A ) Wound-healing assay of the coriloxin-treated CL1-5 cells. We counted cells migrating into the wound area 4 and 8 h after wounding. ( B ) Cell invasion effects exerted by coriloxin (indicated concentrations). The data are representative of three independent experiments and are indicated as the mean ± SD. * p < 0.05 indicates a significant difference from the solvent control group (0.01% DMSO). ( C ) Gelatin zymography assay of MMP-2 and MMP-9 activities in coriloxin-treated cells.

Article Snippet: Our findings suggest that coriloxin can be used as a multitarget anticancer agent.

Techniques: Wound Healing Assay, Solvent, Control, Zymography Assay

Journal: International Journal of Molecular Sciences

Article Title: Coriloxin Exerts Antitumor Effects in Human Lung Adenocarcinoma Cells

doi: 10.3390/ijms23073991

Figure Lengend Snippet: Effects of coriloxin treatment on ERK/AKT and the expression of EMT-related proteins in CL1-5 cells, as determined through Western blot analysis. ( A ) Effects of coriloxin on p-ERK1/2, ERK2, p-AKT, and AKT levels. Cells were treated with 10 µM coriloxin or 0.01% DMSO (solvent control), after which Western blotting revealed the protein expression levels. ( B ) Protein levels of EMT-related genes (Vimentin, N-cad, and E-cad) in CL1-5 cells subjected to 48 h coriloxin treatment (at indicated concentrations). The solvent control group was exposed to 0.01% DMSO. The loading controls were GADPH or α-tubulin. Each experiment was performed, at least, in duplicate.

Article Snippet: Our findings suggest that coriloxin can be used as a multitarget anticancer agent.

Techniques: Expressing, Western Blot, Solvent, Control

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Architecture of kinase's catalytic domain and molecular aspects of spirooxindole scaffold binding at the ATP canonical binding site. (A) Cartoon/surface 3D-representation of the conserved folded tertiary architecture of an example kinase biotarget; CDK2 (PDB_ID: 1qmz ) in complex with ATP molecule (orange sticks), Mg +2 ion (green sphere) and protein substrate (cartoon). Key kinase structural motifs and secondary structures are color-coded. The amino and carboxy-termini are denoted with letters N and C, respectively; (B) Detailed ATP-binding site showing the four main sub-pockets (①–④) for the recognition and binding to main scaffolds of the small molecule kinase inhibitors: (C) key pharmacophoric features of reported small molecule kinase inhibitors and the quite superimposition of the spirooxindole scaffolds over these features. Pharmacophoric features are shown in the 3D-spatial arrangement of color-coded meshed spheres (purple = hydrogen bond acceptor HAcc; blue = hydrogen bond donor HDo, and orange = aromatic rings Aro). Arrows denote the projection/directionality of the hydrogen bonds.

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques: Binding Assay

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of spirooxindole 16.

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthetic routes of spirooxindole derivatives (21a–l).

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of di-spirooxindole derivatives (25a–n).

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of spirooxindole derivatives (28a–m).

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of spirooxindole derivatives (37a–g).

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of spirooxindole derivatives (40a–c).

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of spirooxindole derivatives (43a–o).

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of spirooxindole derivatives (45a–o).

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of spirooxindole derivatives 48a–l.

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of spirooxindole derivatives (8a–h).

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of bi-spirooxindole derivatives 54a–o.

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: RSC Advances

Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

doi: 10.1039/d5ra03404c

Figure Lengend Snippet: Synthesis of spirooxindole derivatives (60a–i).

Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

Techniques:

Journal: Aging (Albany NY)

Article Title: 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks

doi: 10.18632/aging.103565

Figure Lengend Snippet: Effects of BBD24 on proliferation of human osteosarcoma cells and normal blood cells. Cells were treated with BBD24 at indicated concentrations for indicated times. Cell viability was measured by MTT assay. ( A ) IC50 of BBD24 and BBM on human osteosarcoma cells and normal blood cells (peripheral blood mononuclear cells, MBMNCs). ( B , C ) Cell viability of HOS and MG63 after treating with different concentrations of BBD24 and BBM for different times.

Article Snippet: Our findings indicate that BBD24 is a multitarget inhibitor and may represent a new type of anticancer agent for osteosarcoma treatment.

Techniques: MTT Assay

Journal: Aging (Albany NY)

Article Title: 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks

doi: 10.18632/aging.103565

Figure Lengend Snippet: BBD24 down-regulated NF-κB, ERK and AKT signaling pathways of HOS cells. The cells were treated with BBD24 at indicated concentrations for 48 hours, and then nuclear and cytoplasmic proteins were extracted for western blot analysis. β-actin and histone 1 were used as cytoplasmic and nuclear loading controls, respectively. ( A – E ) BBD24 treatment reduced nuclear NF-κB p65 protein level, and inhibited activation of ERK and AKT of HOS cells in dose-dependent manners. Results were expressed as means ± SD of three independent experiments. * P<0.05.

Article Snippet: Our findings indicate that BBD24 is a multitarget inhibitor and may represent a new type of anticancer agent for osteosarcoma treatment.

Techniques: Protein-Protein interactions, Western Blot, Activation Assay

Journal: Aging (Albany NY)

Article Title: 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks

doi: 10.18632/aging.103565

Figure Lengend Snippet: BBD24 induced multiple cell death pathways of HOS cells. Human osteosarcoma HOS cells were treated with BBD24 at 2 μg/ml for indicated times. The cells were harvested by trypsinization and collected by centrifugation for analysis of cell viability, apoptosis and necrosis using flow cytometry assay. HOS osteosarcoma cells were treated with BBD24 at the indicated concentrations for 48 hours, followed by Western blot analysis for caspase family and LC3-II. ( A – C ) Flow cytometry assay indicated that BBD24 induced apoptosis and necrosis of HOS cells with time dependence. ( D – I ) BBD24 promoted activation of caspases and autophagy in HOS cells in a dose-dependent manner. Results were expressed as means ± SD of three independent experiments. * P<0.05.

Article Snippet: Our findings indicate that BBD24 is a multitarget inhibitor and may represent a new type of anticancer agent for osteosarcoma treatment.

Techniques: Centrifugation, Flow Cytometry, Western Blot, Activation Assay

Journal: Aging (Albany NY)

Article Title: 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks

doi: 10.18632/aging.103565

Figure Lengend Snippet: BBD24 suppressed OS cells migration and invasion. 1×10 5 MG63 and HOS cells were seeded on a transwell insert, then treating with different concentrations of BBD24. ( A – C ) BBD24 reduced the migration and invasion of MG63 and HOS cells in a dose dependent manner. Results were expressed as means ± SD of three independent experiments. * P<0.05.

Article Snippet: Our findings indicate that BBD24 is a multitarget inhibitor and may represent a new type of anticancer agent for osteosarcoma treatment.

Techniques: Migration

Journal: Aging (Albany NY)

Article Title: 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks

doi: 10.18632/aging.103565

Figure Lengend Snippet: BBD24 improved cisplatin sensitivity in vitro . HOS cells were treated with BBD24 and/or cisplatin for 72h, then MTT assay was used to measure the cell viability. ( A , B ) HOS cells were treated with different concentrations of BBD24 or cisplatin. ( C ) HOS cells were treated with BBD24 (2 μg/ml) and/or cisplatin (1 μg/ml). ( D ) Cell viability of HOS in cisplatin group and cisplatin+BBD24 group. ( E , F ) IC50 of BBD24, cisplatin, cisplatin+BBD24 (1 μg/ml) and cisplatin+BBD24 (2 μg/ml). Results were expressed as means ± SD of three independent experiments. * P<0.05.

Article Snippet: Our findings indicate that BBD24 is a multitarget inhibitor and may represent a new type of anticancer agent for osteosarcoma treatment.

Techniques: In Vitro, MTT Assay

Journal: Aging (Albany NY)

Article Title: 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks

doi: 10.18632/aging.103565

Figure Lengend Snippet: in vivo anti-tumor activity of BBD24. Nude mice were treated with BBD24 and/or cisplatin for 20 consecutive days. ( A , B ) Tumor volumes in control, cisplatin, BBD24 and BBD24+cisplatin groups. ( C – F ) Immunohistochemical staining of Cleaved-caspase-3, Ki-67 and PCNA in different groups. Results were expressed as means ± SD of three independent experiments. * P<0.05.

Article Snippet: Our findings indicate that BBD24 is a multitarget inhibitor and may represent a new type of anticancer agent for osteosarcoma treatment.

Techniques: In Vivo, Activity Assay, Control, Immunohistochemical staining, Staining

Journal: Aging (Albany NY)

Article Title: 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks

doi: 10.18632/aging.103565

Figure Lengend Snippet: Chemical structure and formula of BBD24.

Article Snippet: Our findings indicate that BBD24 is a multitarget inhibitor and may represent a new type of anticancer agent for osteosarcoma treatment.

Techniques: